825600-90-6

825600-90-6 structure

825600-90-6 structure

Name: Lucinactant
Chemical Name: Lucinactant
CAS Number: 825600-90-6
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Others
Create Date: 2018-07-04 05:36:57
Modify Date: 2024-01-10 11:36:46
Lucinactant is a novel synthetic peptide that functionally mimics surfactant protein B, a protein with anti-inflammatory properties. Lucinactant is a KL4-Surfactant, protects human airway epithelium from hyperoxia[1][2][3].

Name	Lucinactant

Description	Lucinactant is a novel synthetic peptide that functionally mimics surfactant protein B, a protein with anti-inflammatory properties. Lucinactant is a KL4-Surfactant, protects human airway epithelium from hyperoxia[1][2][3].
Related Catalog	Research Areas >> Others Signaling Pathways >> Others >> Others
In Vitro	Lucinactant (140 μL; 24 h and 72 h) provides anti-inflammatory protection compared with an animal-derived surfactant and saline control over 72 h of moderate hyperoxia[1]. Lucinactant (140 μL; 24 h) reduces IL-8 and IL-6 secretion compared with normal saline in hyperoxic exposed Calu-3 monolayers[1]. Lucinactant (140 μL; 24 h) decreases swollen nuclei and intracellular vacuoles in Calu-3 cells after 24 and 72 h of hyperoxia[1]. Cell Viability Assay[1] Cell Line: Hyperoxic exposed Calu-3 monolayers Concentration: 140 μL Incubation Time: 72 hours Result: Demonstrated great cell viability and transepithelial resistance.
In Vivo	Lucinactant (175 mg total phospholipid/5.8 mL/kg; intratracheal medication; single dose) attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of respiratory distress syndrome (RDS)[2]. Animal Model: Preterm lambs (125-128 d gestation)[2] Dosage: 175 mg total phospholipid/kg (5.8 mL/kg) Administration: Intratracheal medication; assessed lung inflammation biomarkers and lung histology at termination Result: Attenuated lung and systemic inflammatory response, supported oxygenation at lower ventilatory requirements, and preserved lung structural integrity to a great degree.
References	[1]. Zhu Y, et al. KL4-surfactant (Lucinactant) protects human airway epithelium from hyperoxia. Pediatr Res. 2008 Aug;64(2):154-8. [2]. Wolfson MR, et al. Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS. Pediatr Res. 2012 Oct;72(4):375-83. [3]. Gastiasoro-Cuesta E, et al. Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome. Pediatrics. 2006 Feb;117(2):295-303.

No Any Chemical & Physical Properties